First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
Journal
Cancer medicine
Date Issued
2023-08-28
Author(s)
Kim, Hye Ryun
Sugawara, Shunichi
Lee, Jong-Seok
Kang, Jin-Hyoung
Inui, Naoki
Hida, Toyoaki
Lee, Ki Hyeong
Yoshida, Tatsuya
Tanaka, Hiroshi
Yang, Cheng-Ta
Nishio, Makoto
Ohe, Yuichiro
Tamura, Tomohide
Yamamoto, Nobuyuki
Akamatsu, Hiroaki
Takahashi, Shigeru
Nakagawa, Kazuhiko
Abstract
ONO-4538-52/TASUKI-52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first-line) treatment of patients with advanced non-squamous non-small cell lung cancer (nsNSCLC). At the interim analysis (minimum follow-up, 7.4 months), the independent radiology review committee-assessed progression-free survival was significantly longer in the nivolumab arm, but overall survival (OS) data were immature.
Subjects
bevacizumab; chemotherapy; nivolumab; non-squamous non-small cell lung cancer; survival
SDGs
Type
journal article